| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 37 | 2022 | 107 | 3.220 |
Why?
|
| Genetic Predisposition to Disease | 35 | 2019 | 368 | 1.760 |
Why?
|
| Polymorphism, Single Nucleotide | 32 | 2019 | 270 | 1.210 |
Why?
|
| Genome-Wide Association Study | 18 | 2021 | 276 | 1.040 |
Why?
|
| Genetic Linkage | 16 | 2021 | 33 | 0.740 |
Why?
|
| Schizophrenia | 10 | 2019 | 51 | 0.660 |
Why?
|
| Chromosomes, Human, Pair 16 | 4 | 2011 | 5 | 0.600 |
Why?
|
| Genetic Variation | 11 | 2018 | 97 | 0.580 |
Why?
|
| Genome, Human | 9 | 2021 | 45 | 0.560 |
Why?
|
| Genetic Association Studies | 3 | 2015 | 84 | 0.480 |
Why?
|
| Linkage Disequilibrium | 13 | 2018 | 35 | 0.430 |
Why?
|
| Psychotic Disorders | 6 | 2019 | 36 | 0.420 |
Why?
|
| Pedigree | 14 | 2015 | 55 | 0.360 |
Why?
|
| Haplotypes | 11 | 2018 | 56 | 0.340 |
Why?
|
| Humans | 61 | 2022 | 27192 | 0.330 |
Why?
|
| Antineoplastic Agents | 3 | 2009 | 202 | 0.320 |
Why?
|
| Genotype | 16 | 2019 | 344 | 0.320 |
Why?
|
| Autistic Disorder | 4 | 2011 | 40 | 0.300 |
Why?
|
| Polymorphism, Genetic | 5 | 2008 | 56 | 0.300 |
Why?
|
| Cisplatin | 2 | 2008 | 61 | 0.290 |
Why?
|
| Carrier Proteins | 4 | 2009 | 98 | 0.270 |
Why?
|
| Family Health | 9 | 2012 | 31 | 0.260 |
Why?
|
| Phenotype | 10 | 2015 | 312 | 0.260 |
Why?
|
| Alleles | 10 | 2019 | 208 | 0.250 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2009 | 68 | 0.250 |
Why?
|
| Male | 33 | 2021 | 14838 | 0.240 |
Why?
|
| Chromosome Mapping | 9 | 2012 | 28 | 0.240 |
Why?
|
| Female | 33 | 2021 | 15292 | 0.240 |
Why?
|
| Mental Disorders | 2 | 2018 | 142 | 0.230 |
Why?
|
| Homeodomain Proteins | 2 | 2018 | 60 | 0.220 |
Why?
|
| Microsatellite Repeats | 6 | 2012 | 10 | 0.220 |
Why?
|
| Gene Regulatory Networks | 3 | 2022 | 29 | 0.220 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 3 | 2015 | 33 | 0.200 |
Why?
|
| Case-Control Studies | 9 | 2019 | 589 | 0.200 |
Why?
|
| Chromosomes, Human, Pair 13 | 4 | 2017 | 4 | 0.200 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2022 | 26 | 0.190 |
Why?
|
| Personality | 2 | 2013 | 53 | 0.190 |
Why?
|
| Obsessive-Compulsive Disorder | 2 | 2012 | 17 | 0.190 |
Why?
|
| Cell Proliferation | 3 | 2018 | 179 | 0.180 |
Why?
|
| Family | 5 | 2015 | 102 | 0.170 |
Why?
|
| Neural Cell Adhesion Molecules | 1 | 2019 | 1 | 0.160 |
Why?
|
| Lateral Ventricles | 1 | 2019 | 5 | 0.160 |
Why?
|
| Calcium-Binding Proteins | 1 | 2019 | 22 | 0.160 |
Why?
|
| Adult | 15 | 2019 | 7932 | 0.160 |
Why?
|
| POU Domain Factors | 1 | 2018 | 2 | 0.150 |
Why?
|
| Temperament | 3 | 2013 | 11 | 0.150 |
Why?
|
| Genetic Loci | 1 | 2019 | 51 | 0.150 |
Why?
|
| Pharmacogenetics | 3 | 2014 | 6 | 0.150 |
Why?
|
| Lod Score | 7 | 2021 | 11 | 0.150 |
Why?
|
| Young Adult | 8 | 2019 | 2026 | 0.150 |
Why?
|
| Homosexuality, Male | 1 | 2017 | 28 | 0.140 |
Why?
|
| Lymphocytes | 3 | 2008 | 59 | 0.140 |
Why?
|
| Gene Frequency | 9 | 2007 | 57 | 0.140 |
Why?
|
| Inheritance Patterns | 3 | 2015 | 7 | 0.130 |
Why?
|
| Brain | 3 | 2018 | 1649 | 0.130 |
Why?
|
| Membrane Proteins | 4 | 2017 | 171 | 0.130 |
Why?
|
| Chromosomes, Human, X | 1 | 2016 | 8 | 0.130 |
Why?
|
| Receptor, ErbB-2 | 1 | 2016 | 52 | 0.130 |
Why?
|
| Pursuit, Smooth | 1 | 2015 | 1 | 0.120 |
Why?
|
| Child | 8 | 2015 | 1267 | 0.120 |
Why?
|
| Siblings | 1 | 2015 | 14 | 0.120 |
Why?
|
| Behavior | 1 | 2015 | 25 | 0.120 |
Why?
|
| Receptors, Metabotropic Glutamate | 1 | 2014 | 13 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 15 | 2 | 2011 | 4 | 0.110 |
Why?
|
| Adolescent | 7 | 2018 | 2179 | 0.110 |
Why?
|
| Antipsychotic Agents | 1 | 2014 | 54 | 0.110 |
Why?
|
| Memory, Short-Term | 1 | 2014 | 96 | 0.110 |
Why?
|
| Sulfotransferases | 1 | 2013 | 6 | 0.100 |
Why?
|
| Depressive Disorder, Major | 4 | 2019 | 99 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 18 | 2 | 2003 | 6 | 0.100 |
Why?
|
| Glucose Transporter Type 2 | 1 | 2012 | 1 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2012 | 10 | 0.100 |
Why?
|
| Delusions | 1 | 2012 | 9 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2012 | 7 | 0.100 |
Why?
|
| Neurons | 1 | 2015 | 340 | 0.100 |
Why?
|
| Amino Acid Transport System X-AG | 1 | 2011 | 1 | 0.090 |
Why?
|
| Psychiatric Status Rating Scales | 4 | 2018 | 309 | 0.090 |
Why?
|
| Chromosome Deletion | 2 | 2008 | 16 | 0.090 |
Why?
|
| Microarray Analysis | 1 | 2011 | 8 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2011 | 76 | 0.090 |
Why?
|
| Signal Transduction | 2 | 2015 | 446 | 0.090 |
Why?
|
| Cell Line, Tumor | 3 | 2009 | 264 | 0.090 |
Why?
|
| Gene Expression Profiling | 1 | 2011 | 143 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2009 | 5 | 0.080 |
Why?
|
| Carboplatin | 1 | 2009 | 26 | 0.080 |
Why?
|
| Etoposide | 1 | 2008 | 27 | 0.080 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 9 | 0.080 |
Why?
|
| Middle Aged | 7 | 2019 | 9045 | 0.080 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2008 | 6 | 0.080 |
Why?
|
| Neurotransmitter Agents | 1 | 2008 | 16 | 0.080 |
Why?
|
| Trans-Activators | 1 | 2008 | 23 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2008 | 3 | 0.080 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2008 | 1 | 0.080 |
Why?
|
| Personality Inventory | 3 | 2013 | 73 | 0.080 |
Why?
|
| PPAR delta | 1 | 2008 | 1 | 0.080 |
Why?
|
| Age of Onset | 4 | 2012 | 95 | 0.070 |
Why?
|
| Genomics | 1 | 2008 | 65 | 0.070 |
Why?
|
| DNA Methylation | 1 | 2010 | 164 | 0.070 |
Why?
|
| Chromosome Aberrations | 1 | 2008 | 17 | 0.070 |
Why?
|
| Gene Dosage | 1 | 2008 | 19 | 0.070 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2008 | 2 | 0.070 |
Why?
|
| Proteins | 1 | 2008 | 64 | 0.070 |
Why?
|
| Wnt Proteins | 1 | 2008 | 22 | 0.070 |
Why?
|
| Receptors, Dopamine D2 | 1 | 2008 | 11 | 0.070 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 65 | 0.070 |
Why?
|
| Caffeine | 1 | 2008 | 57 | 0.070 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2007 | 7 | 0.070 |
Why?
|
| DNA Mutational Analysis | 4 | 2009 | 55 | 0.070 |
Why?
|
| Receptors, Cholinergic | 1 | 2007 | 24 | 0.070 |
Why?
|
| Daunorubicin | 1 | 2007 | 5 | 0.070 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2009 | 54 | 0.070 |
Why?
|
| Cerebellum | 2 | 2022 | 39 | 0.070 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2007 | 17 | 0.070 |
Why?
|
| Sequence Analysis, DNA | 4 | 2011 | 57 | 0.070 |
Why?
|
| Apoptosis | 1 | 2008 | 210 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 2 | 1 | 2006 | 1 | 0.070 |
Why?
|
| Suicide, Attempted | 1 | 2006 | 14 | 0.070 |
Why?
|
| Anxiety Disorders | 1 | 2008 | 170 | 0.070 |
Why?
|
| Receptors, Vasopressin | 1 | 2005 | 1 | 0.060 |
Why?
|
| Exons | 3 | 2011 | 33 | 0.060 |
Why?
|
| Sexual Dysfunctions, Psychological | 1 | 2005 | 10 | 0.060 |
Why?
|
| Serotonin Plasma Membrane Transport Proteins | 1 | 2005 | 12 | 0.060 |
Why?
|
| Receptors, Dopamine D4 | 1 | 2005 | 3 | 0.060 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 1 | 2005 | 5 | 0.060 |
Why?
|
| Dopamine Plasma Membrane Transport Proteins | 1 | 2005 | 5 | 0.060 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 236 | 0.060 |
Why?
|
| Odds Ratio | 3 | 2013 | 277 | 0.060 |
Why?
|
| Puberty | 1 | 2004 | 11 | 0.060 |
Why?
|
| Gene Expression Regulation | 2 | 2018 | 272 | 0.060 |
Why?
|
| Brain-Derived Neurotrophic Factor | 1 | 2004 | 46 | 0.060 |
Why?
|
| Genetic Markers | 3 | 2012 | 34 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2018 | 673 | 0.050 |
Why?
|
| Factor Analysis, Statistical | 2 | 2015 | 55 | 0.050 |
Why?
|
| Costa Rica | 2 | 2015 | 2 | 0.050 |
Why?
|
| RNA, Messenger | 2 | 2018 | 310 | 0.050 |
Why?
|
| Glucuronosyltransferase | 1 | 2003 | 4 | 0.050 |
Why?
|
| Genes | 1 | 2003 | 6 | 0.050 |
Why?
|
| Morphine | 1 | 2003 | 72 | 0.050 |
Why?
|
| Mice | 2 | 2022 | 1414 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2002 | 4 | 0.050 |
Why?
|
| D-Amino-Acid Oxidase | 1 | 2022 | 1 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2002 | 1 | 0.050 |
Why?
|
| Mannosyltransferases | 1 | 2002 | 2 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2002 | 5 | 0.050 |
Why?
|
| Genetic Heterogeneity | 2 | 2013 | 9 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 257 | 0.040 |
Why?
|
| Sexual Behavior | 1 | 2021 | 52 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2003 | 230 | 0.040 |
Why?
|
| Quantitative Trait Loci | 2 | 2010 | 44 | 0.040 |
Why?
|
| Systems Biology | 1 | 2019 | 6 | 0.040 |
Why?
|
| Animals | 2 | 2022 | 3625 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2010 | 59 | 0.040 |
Why?
|
| Databases, Genetic | 1 | 2018 | 8 | 0.040 |
Why?
|
| Neural Stem Cells | 1 | 2018 | 13 | 0.040 |
Why?
|
| Postmortem Changes | 1 | 2018 | 32 | 0.040 |
Why?
|
| Neuroimaging | 1 | 2019 | 129 | 0.040 |
Why?
|
| Gene Expression | 2 | 2010 | 200 | 0.040 |
Why?
|
| Models, Statistical | 1 | 2018 | 127 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2018 | 135 | 0.040 |
Why?
|
| Chromosomes, Artificial, Bacterial | 2 | 2008 | 3 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 192 | 0.040 |
Why?
|
| X Chromosome Inactivation | 1 | 2017 | 1 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2017 | 2 | 0.040 |
Why?
|
| Receptors, Thyrotropin | 1 | 2017 | 5 | 0.040 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 118 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2009 | 331 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2013 | 1156 | 0.030 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 39 | 0.030 |
Why?
|
| United States | 3 | 2012 | 2075 | 0.030 |
Why?
|
| Epistasis, Genetic | 2 | 2008 | 8 | 0.030 |
Why?
|
| Prognosis | 1 | 2018 | 804 | 0.030 |
Why?
|
| Korea | 2 | 2005 | 10 | 0.030 |
Why?
|
| Principal Component Analysis | 1 | 2015 | 23 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2012 | 1802 | 0.030 |
Why?
|
| Models, Genetic | 1 | 2015 | 34 | 0.030 |
Why?
|
| Statistics, Nonparametric | 2 | 2006 | 119 | 0.030 |
Why?
|
| Aged | 3 | 2018 | 9101 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2019 | 1105 | 0.030 |
Why?
|
| National Institute of Mental Health (U.S.) | 2 | 2004 | 3 | 0.030 |
Why?
|
| Endophenotypes | 1 | 2013 | 11 | 0.030 |
Why?
|
| Irritable Mood | 1 | 2013 | 3 | 0.030 |
Why?
|
| Child Development Disorders, Pervasive | 1 | 2013 | 16 | 0.030 |
Why?
|
| Crohn Disease | 1 | 2013 | 40 | 0.030 |
Why?
|
| Cross-Cultural Comparison | 1 | 2013 | 39 | 0.030 |
Why?
|
| Jews | 1 | 2013 | 4 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2007 | 893 | 0.030 |
Why?
|
| Parvalbumins | 1 | 2012 | 1 | 0.030 |
Why?
|
| DNA, Complementary | 2 | 2003 | 26 | 0.030 |
Why?
|
| Psychometrics | 1 | 2013 | 218 | 0.020 |
Why?
|
| Calcium Channels | 1 | 2012 | 107 | 0.020 |
Why?
|
| Computational Biology | 1 | 2011 | 21 | 0.020 |
Why?
|
| Validation Studies as Topic | 1 | 2011 | 3 | 0.020 |
Why?
|
| Selection Bias | 1 | 2011 | 7 | 0.020 |
Why?
|
| Reference Standards | 1 | 2011 | 23 | 0.020 |
Why?
|
| Sample Size | 1 | 2011 | 18 | 0.020 |
Why?
|
| Neuropsychological Tests | 1 | 2015 | 1198 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2011 | 42 | 0.020 |
Why?
|
| ROC Curve | 1 | 2011 | 141 | 0.020 |
Why?
|
| Databases, Nucleic Acid | 1 | 2010 | 1 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2012 | 623 | 0.020 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2011 | 137 | 0.020 |
Why?
|
| CpG Islands | 1 | 2010 | 54 | 0.020 |
Why?
|
| Cloning, Molecular | 1 | 2009 | 29 | 0.020 |
Why?
|
| Research Design | 1 | 2011 | 187 | 0.020 |
Why?
|
| Embryo, Mammalian | 1 | 2009 | 25 | 0.020 |
Why?
|
| Semaphorins | 1 | 2008 | 1 | 0.020 |
Why?
|
| Methyltransferases | 1 | 2008 | 2 | 0.020 |
Why?
|
| Protein-Arginine N-Methyltransferases | 1 | 2008 | 2 | 0.020 |
Why?
|
| Amino Acid Transport Systems, Basic | 1 | 2008 | 2 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2009 | 95 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 81 | 0.020 |
Why?
|
| CLOCK Proteins | 1 | 2008 | 16 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 34 | 0.020 |
Why?
|
| Wnt3 Protein | 1 | 2008 | 1 | 0.020 |
Why?
|
| Risk Factors | 1 | 2015 | 2336 | 0.020 |
Why?
|
| LIM Domain Proteins | 1 | 2008 | 2 | 0.020 |
Why?
|
| China | 1 | 2008 | 48 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 4 | 1 | 2008 | 3 | 0.020 |
Why?
|
| Gene Duplication | 1 | 2008 | 4 | 0.020 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2008 | 9 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2008 | 94 | 0.020 |
Why?
|
| Cell Line | 1 | 2008 | 271 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 15 | 0.020 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 14 | 0.020 |
Why?
|
| Adenosine | 1 | 2008 | 8 | 0.020 |
Why?
|
| Glycoproteins | 1 | 2008 | 49 | 0.020 |
Why?
|
| Chromosome Breakage | 1 | 2007 | 3 | 0.020 |
Why?
|
| Self-Assessment | 1 | 2008 | 29 | 0.020 |
Why?
|
| DNA Primers | 1 | 2007 | 51 | 0.020 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2007 | 37 | 0.020 |
Why?
|
| Brain Chemistry | 1 | 2008 | 45 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2008 | 56 | 0.020 |
Why?
|
| Base Sequence | 1 | 2007 | 106 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2008 | 157 | 0.020 |
Why?
|
| Choline O-Acetyltransferase | 1 | 2007 | 21 | 0.020 |
Why?
|
| Dopamine | 1 | 2008 | 82 | 0.020 |
Why?
|
| Cognition | 1 | 2015 | 1338 | 0.020 |
Why?
|
| Minisatellite Repeats | 1 | 2005 | 8 | 0.020 |
Why?
|
| Introns | 1 | 2005 | 17 | 0.020 |
Why?
|
| Treatment Outcome | 1 | 2014 | 3525 | 0.020 |
Why?
|
| Filamins | 1 | 2005 | 3 | 0.010 |
Why?
|
| Contractile Proteins | 1 | 2005 | 3 | 0.010 |
Why?
|
| Microfilament Proteins | 1 | 2005 | 24 | 0.010 |
Why?
|
| Immunoglobulins | 1 | 2005 | 13 | 0.010 |
Why?
|
| DNA | 1 | 2005 | 102 | 0.010 |
Why?
|
| Logistic Models | 1 | 2005 | 398 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 309 | 0.010 |
Why?
|
| Chromosomes, Human | 1 | 2003 | 6 | 0.010 |
Why?
|
| Sex Factors | 1 | 2005 | 467 | 0.010 |
Why?
|
| Morphine Derivatives | 1 | 2003 | 1 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 11 | 0.010 |
Why?
|
| Biotransformation | 1 | 2003 | 6 | 0.010 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2003 | 22 | 0.010 |
Why?
|
| Alternative Splicing | 1 | 2003 | 21 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2003 | 27 | 0.010 |
Why?
|
| Glycosylation | 1 | 2002 | 20 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2002 | 37 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2004 | 1380 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 2003 | 4837 | 0.010 |
Why?
|